PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Early Diagnosis and Targeted Therapy to Address Unmet Need in European Breast Cancer Therapeutics Market - New analysis from Frost & Sullivan, European Markets for Breast Cancer Therapeutics, finds that the market earned revenues of $1.72 billion in 2006 and estimates this to reach $2.9 billion in 2013
Early Diagnosis and Targeted Therapy to Address Unmet Need in European Breast Cancer Therapeutics Market

 

NewswireToday - /newswire/ - London, United Kingdom, 2007/11/06 - New analysis from Frost & Sullivan, European Markets for Breast Cancer Therapeutics, finds that the market earned revenues of $1.72 billion in 2006 and estimates this to reach $2.9 billion in 2013.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

The greatest unmet need of all breast cancer patients is a cure. A variety of drugs are used to treat breast cancer in stages III and IV. However, they only act to control the progression of the disease and can be associated with side effects that can cause significant disruption to patients' quality of life. In those who respond, the tumour can be controlled for many years. However, in most cases, survival is not greatly extended. This situation is creating a real and immediate need for effective, targeted therapeutics.

New analysis from Frost & Sullivan (pharma.frost.com), European Markets for Breast Cancer Therapeutics, finds that the market earned revenues of $1.72 billion in 2006 and estimates this to reach $2.9 billion in 2013.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the European Markets for Breast Cancer Therapeutics, then send an email to Radhika Menon Theodore, Corporate Communications, at rmtheodore[.]frost.com, with your full name, company name, title, telephone number, fax number, and email address. Upon receipt of the above information, an overview will be sent to you by email.

"Fifteen per cent of breast cancer cases are detected at a metastatic stage and approximately 50 per cent of those detected at an early stage will progress to stages III and IV," states Frost & Sullivan Research Analyst Sriram V. "In the advanced stages of the disease, the chances of being cured with the current therapies are bleak, opening up opportunities for improved diagnostic techniques and development of breast cancer therapeutics with a good safety profile."

Chemotherapeutic side effects present a significant challenge to the breast cancer therapeutics market. Biologics are considered to be the alternative, with a host of products anticipated to enter the market post 2008. However, clinical trials and their lengthy duration are a concern that companies should address before determining the timing of their product launch.

At present, the only commercially available offering in the biologics sector is Herceptin. A huge barrier to the widespread adoption of biologics will be the high cost of treatment. Pressure on margins and high prices due to the high cost of development may not continue for long, as prescribing trends are subject to governmental regulations and available literature.

"A single Herceptin injection is estimated to cost $3,500, while a whole course over a nine month period may cost up to $60,000" comments Sriram. "This challenge will have a limited effect in the early stages of the market, since only one biologic is currently available, but is anticipated to have a greater impact after 2008, as more biopharmaceutical products enter the global breast cancer therapeutics market."

Cancer therapeutics are the most expensive to bring to market, owing mostly to the costs involved in administering clinical trials. A potential strategy to counteract this challenge will be to attract commercial partners to support drug development and marketing. Large multinationals are comparatively receptive to such proposals if the product shows promise in the pre-clinical stages.

European Markets for Breast Cancer Therapeutics is part of the Pharmaceuticals and Biotechnology Growth Partnership Service programme, which also includes research in the following markets: European Markets for Lung Cancer Therapeutics. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.

About Frost & Sullivan
Frost & Sullivan, the Growth Consulting Company, partners with clients to accelerate their growth. The company's Growth Partnership Services, Growth Consulting and Career Best Practices empower clients to create a growth focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Early Diagnosis and Targeted Therapy to Address Unmet Need in European Breast Cancer Therapeutics Market

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Radhika Menon Theodore 
rmtheodore[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Frost & Sullivan Commends Nemaura for Developing Superior Transdermal Drug Delivery Technology Platforms, the Memspatch and Micropatch
Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  Triggr & Bloom





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)